Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 1Nose Neoplasms 1Esthesioneuroblastoma, Olfactory 1Cancer Diagnosis 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × Radionuclide Imaging × Clear all
NCT05012098 2025-08-08

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 14 charts
CNS

Nose Neoplasms, Esthesioneuroblastoma, Olfactory

NCT05141760 2024-06-06

18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients

University of Alberta

Phase 2 Completed
150 enrolled
Genitourinary

Prostatic Neoplasms

NCT03125629 2021-04-09

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

Stanford University

Phase 2 Completed
53 enrolled 8 charts

Cancer Diagnosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡